Epacadostat/Pembrolizumab Promising in Advanced Bladder Cancer in Early Trial

The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma.

Source: CancerNetwork - June 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news